CT textural analysis of gastric cancer: correlations with immunohistochemical biomarkers

To investigate the ability of CT texture analysis to assess and predict the expression statuses of E-cadherin, Ki67, VEGFR2 and EGFR in gastric cancers, the enhanced CT images of 139 patients with gastric cancer were retrospectively reviewed. The region of interest was manually drawn along the margin of the lesion on the largest slice in the arterial and venous phases, which yielded a series of texture parameters. Our results showed that the standard deviation, width, entropy, entropy (H), correlation and contrast from the arterial and venous phases were significantly correlated with the E-cadherin expression level in gastric cancers (all P < 0.05). The skewness from the arterial phase and the mean and autocorrelation from the venous phase were negatively correlated with the Ki67 expression level in gastric cancers (all P < 0.05). The width, entropy and contrast from the venous phase were positively correlated with the VEGFR2 expression level in gastric cancers (all P < 0.05). No significant correlation was found between the texture features and EGFR expression level. CT texture analysis, which had areas under the receiver operating characteristic curve (AUCs) ranging from 0.612 to 0.715, holds promise in predicting E-cadherin, Ki67 and VEGFR2 expression levels in gastric cancers.

[1]  Perry J Pickhardt,et al.  CT Texture Analysis: Definitions, Applications, Biologic Correlates, and Challenges. , 2017, Radiographics : a review publication of the Radiological Society of North America, Inc.

[2]  Y. Doki,et al.  Accuracy of multidetector-row CT in diagnosing lymph node metastasis in patients with gastric cancer , 2015, European Radiology.

[3]  W. Kim,et al.  Low Ki‐67 proliferation index is an indicator of poor prognosis in gastric cancer , 2010, Journal of surgical oncology.

[4]  Xin He,et al.  Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis , 2014, BMC Cancer.

[5]  V. Goh,et al.  Primary esophageal cancer: heterogeneity as potential prognostic biomarker in patients treated with definitive chemotherapy and radiation therapy. , 2013, Radiology.

[6]  Kui-Sheng Chen,et al.  Spectral computed tomography in advanced gastric cancer: Can iodine concentration non-invasively assess angiogenesis? , 2017, World journal of gastroenterology.

[7]  Alan D. Lopez,et al.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study , 2017, JAMA oncology.

[8]  V. Goh,et al.  Assessment of primary colorectal cancer heterogeneity by using whole-tumor texture analysis: contrast-enhanced CT texture as a biomarker of 5-year survival. , 2013, Radiology.

[9]  E. Fishman,et al.  Hypervascular gastric masses: CT findings and clinical correlates. , 2010, AJR. American journal of roentgenology.

[10]  H. Honda,et al.  Extent of arterial tumor enhancement measured with preoperative MDCT gastrography is a prognostic factor in advanced gastric cancer after curative resection. , 2013, AJR. American journal of roentgenology.

[11]  R. Sutradhar,et al.  A systematic review and meta-analysis of the utility of EUS for preoperative staging for gastric cancer , 2012, Gastric Cancer.

[12]  Z. Wang,et al.  Combined evaluation of centromere protein H and Ki-67 as prognostic biomarker for patients with gastric carcinoma. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[13]  Yihong Sun,et al.  Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. , 2010, World journal of gastroenterology.

[14]  P. Kim,et al.  Gastric cancer staging at multi-detector row CT gastrography: comparison of transverse and volumetric CT scanning. , 2005, Radiology.

[15]  Francesco Giganti,et al.  Gastric cancer: texture analysis from multidetector computed tomography as a potential preoperative prognostic biomarker , 2017, European Radiology.

[16]  Jian He,et al.  Application of CT texture analysis in predicting histopathological characteristics of gastric cancers , 2017, European Radiology.

[17]  Gerhard Christofori,et al.  A causal role for E-cadherin in the transition from adenoma to carcinoma , 1998, Nature.

[18]  Dan Zhou,et al.  [Correlation of CT presentation with histo-differentiation and p53 and Ki67 expressions in gastric cancer]. , 2011, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae.

[19]  F. Giganti,et al.  Preoperative locoregional staging of gastric cancer: is there a place for magnetic resonance imaging? Prospective comparison with EUS and multidetector computed tomography , 2015, Gastric Cancer.

[20]  Alejandro Munoz del Rio,et al.  CT textural analysis of hepatic metastatic colorectal cancer: pre-treatment tumor heterogeneity correlates with pathology and clinical outcomes , 2015, Abdominal Imaging.

[21]  J. Gerdes Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. , 1990, Seminars in cancer biology.

[22]  F. Roviello,et al.  Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. , 2016, Cancer letters.

[23]  Jie Ma,et al.  Prognostic evaluation of Nanog, Oct4, Sox2, PCNA, Ki67 and E-cadherin expression in gastric cancer , 2014, Medical Oncology.

[24]  Sang Joon Park,et al.  Prediction of the therapeutic response after FOLFOX and FOLFIRI treatment for patients with liver metastasis from colorectal cancer using computerized CT texture analysis. , 2016, European journal of radiology.

[25]  Nicola Schieda,et al.  Can Quantitative CT Texture Analysis be Used to Differentiate Fat-poor Renal Angiomyolipoma from Renal Cell Carcinoma on Unenhanced CT Images? , 2015, Radiology.

[26]  R. Thornhill,et al.  Quantitative CT texture and shape analysis: Can it differentiate benign and malignant mediastinal lymph nodes in patients with primary lung cancer? , 2015, European Radiology.

[27]  R. Wirtz,et al.  The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer , 2012, BMC Cancer.

[28]  Vicky Goh,et al.  Assessment of tumor heterogeneity by CT texture analysis: can the largest cross-sectional area be used as an alternative to whole tumor analysis? , 2013, European journal of radiology.

[29]  S. Kobayashi,et al.  Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. , 2014, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[30]  Francesco Giganti,et al.  Pre-treatment MDCT-based texture analysis for therapy response prediction in gastric cancer: Comparison with tumour regression grade at final histology. , 2017, European journal of radiology.

[31]  Richard D. White,et al.  CT Gray-Level Texture Analysis as a Quantitative Imaging Biomarker of Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma of the Lung. , 2015, AJR. American journal of roentgenology.

[32]  M. Naghavi,et al.  Exclusion of Kaposi Sarcoma From Analysis of Cancer Burden-Reply. , 2017, JAMA oncology.

[33]  Yongfei Wang,et al.  The prognostic value of E‐cadherin in gastric cancer: A meta‐analysis , 2013, International journal of cancer.

[34]  Y. Saito,et al.  Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma. , 2000, Gynecologic oncology.

[35]  Y. Yatabe,et al.  Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer , 2010, The FEBS journal.

[36]  M. Anzidei,et al.  Analysis of CT features and quantitative texture analysis in patients with lung adenocarcinoma: a correlation with EGFR mutations and survival rates. , 2017, Clinical radiology.

[37]  M. Huang,et al.  Loss of E-cadherin expression correlates with poor differentiation and invasion into adjacent organs in gastric adenocarcinomas. , 2003, Cancer letters.

[38]  Mohammad Hossein Khosravi,et al.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016 , 2018, JAMA oncology.

[39]  Z. Chang,et al.  Relationship between expression of EGFR in gastric cancer tissue and clinicopathological features. , 2013, Asian Pacific journal of tropical medicine.

[40]  L. Ellis,et al.  Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  F. Schmidt Meta-Analysis , 2008 .

[42]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[43]  C. Fuchs,et al.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.